Mount Sinai & Sema4 scientists identify biomarker for progression and drug response in brain cancer

(The Mount Sinai Hospital / Mount Sinai School of Medicine) Scientists at the Icahn School of Medicine at Mount Sinai, Sema4, and collaborating institutions including Colorado State University and Fred Hutchinson Cancer Center reported results today from a glioblastoma study in which they validated a biomarker indicative of a patient's prognosis and likely response to specific therapies.